Nanoparticles for drug delivery in cancer treatment

Urologic Oncology
Barbara Haley, Eugene Frenkel

Abstract

Nanoparticles (size in nanometer range) provide a new mode of cancer drug delivery functioning as a carrier for entry through fenestrations in tumor vasculature allowing direct cell access. These particles allow exquisite modification for binding to cancer cell membranes, the microenvironment, or to cytoplasmic or nuclear receptor sites. This results in delivery of high drug concentrations to the targeted cancer cell, with reduced toxicity of normal tissue. Several such engineered drugs are in clinical practice, including liposomal doxorubicin and albumin conjugate paclitaxel. The carrier mediated paclitaxel has already shown significant efficacy in taxane resistant cancers, an approach highly relevant in prostate cancer, where taxanes are the treatment of choice. Other modifications including transferrin receptor and folate receptor targeted drug delivery molecules are in study. This new technology provides many exciting therapeutic approaches for targeted high concentration drug delivery to cancer cells with reduced injury of normal cells.

References

Jan 1, 1982·Journal of Cancer Research and Clinical Oncology·P Shubik
Dec 12, 1980·Science·M B YatvinM Shinitzky
Apr 11, 1996·Nature·D D Lasic
Jun 20, 1998·Seminars in Radiation Oncology·F Yuan
Mar 4, 2000·Advanced Drug Delivery Reviews·J Sudimack, R J Lee
Mar 17, 2000·Biochimica Et Biophysica Acta·M PurcellH A Tajmir-Riahi
Jun 6, 2000·Advanced Drug Delivery Reviews·D F Baban, L W Seymour
Mar 30, 2001·European Journal of Biochemistry·K PaálL Hegedûs
Oct 31, 2003·Expert Reviews in Molecular Medicine·M Links, R Brown
Sep 8, 2004·International Journal of Cancer. Journal International Du Cancer·Sanjeeb K SahooVinod Labhasetwar
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Mar 5, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S Moein MoghimiJ Clifford Murray
Jul 20, 2005·Anti-cancer Drugs·Ralf-Dieter HofheinzAndreas Hochhaus
Jul 21, 2005·Technology in Cancer Research & Treatment·Jaspreet K Vasir, Vinod Labhasetwar
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William J GradisharJoyce O'Shaughnessy
Nov 25, 2005·Current Drug Delivery·Yoshiyuki Hattori, Yoshie Maitani
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Neil DesaiPatrick Soon-Shiong
Apr 12, 2006·Proceedings of the National Academy of Sciences of the United States of America·Omid C FarokhzadRobert Langer
May 11, 2006·International Journal of Molecular Medicine·Yiqun CheZhihua Liu
Feb 13, 2007·Nanomedicine : Nanotechnology, Biology, and Medicine·Gareth A Hughes

❮ Previous
Next ❯

Citations

Aug 7, 2013·Nanomedicine·Pranali P DeshpandeVladimir P Torchilin
Nov 15, 2012·Future Oncology·Pengxiao Cao, Younsoo Bae
Sep 13, 2013·Therapeutic Delivery·Diego Dos Santos FerreiraMônica Cristina Oliveira
Nov 1, 2010·Therapeutic Delivery·Himanshu BhattacharjeeGeorge C Wood
Jul 31, 2012·Therapeutic Delivery·M H D Kamal Al-HallakRaimar Löbenberg
May 27, 2014·Journal of Photochemistry and Photobiology. B, Biology·Supriya SrinivasanAnthony J McGoron
Feb 5, 2014·Advanced Drug Delivery Reviews·Swapnil V BhujbalSimone P Niclou
Sep 27, 2014·Nanoscale Research Letters·Yang Gao, Zhou Yuan
Feb 22, 2014·Pharmaceutical Research·Hasti RouhaniRassoul Dinarvand
Jul 23, 2014·Critical Reviews in Oncology/hematology·A ViúdezM Hidalgo
Sep 16, 2011·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Wayne L MonskyDaniel P Link
Oct 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Hui DingJulia Y Ljubimova
Oct 5, 2011·Proceedings of the National Academy of Sciences of the United States of America·Lilach AgemyErkki Ruoslahti
Jan 13, 2012·Chinese Journal of Cancer·Xue Xue, Xing-Jie Liang
Mar 13, 2012·The AAPS Journal·Neil Desai
Sep 11, 2013·Proceedings of the National Academy of Sciences of the United States of America·Joshua J KaufmanAyman F Abouraddy
Nov 19, 2009·Journal of Materials Science. Materials in Medicine·Peifeng LiuYourong Duan
Aug 21, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lilach AgemyErkki Ruoslahti
Jun 10, 2010·Nanomedicine·Xiaowei Dong, Russell J Mumper
Aug 7, 2013·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·C MattuZ Ramtoola
Aug 3, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A S GonçalvesE B Souto
Dec 15, 2012·Nano Reviews·Grant L ZwickeConstance J Jeffery
Jul 21, 2010·Medical Oncology·Shuyan MengZhou Caicun
Oct 22, 2013·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Wei ShiKun-Yu Yang
Oct 6, 2011·Journal of Microencapsulation·Khushwant S YadavKrutika K Sawant
Jan 15, 2016·Protein Engineering, Design & Selection : PEDS·Amanda L GrossValery A Petrenko
Oct 17, 2015·International Journal of Molecular Sciences·Feng JiangGe Zhang
Dec 24, 2011·Drug Development and Industrial Pharmacy·Stephanie Bosselmann, Robert O Williams
Feb 26, 2014·Drug Development and Industrial Pharmacy·Chengyun YanAkira Yamamoto
Mar 29, 2012·Expert Opinion on Drug Delivery·Payam ZahediChristine Allen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Caveolins & Signal Transduction

Caveolins are small proteins with a hairpin loop conformation that are located in the plasma membrane of various cell types where they bind cholesterol and interact with receptors essential for several signal transduction pathways. Here is the latest research.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Advanced Drug Delivery Reviews
James D ByrneLisa Brannon-Peppas
Advanced Drug Delivery Reviews
Irène BriggerPatrick Couvreur
Journal of Controlled Release : Official Journal of the Controlled Release Society
H MaedaK Hori
Journal of Controlled Release : Official Journal of the Controlled Release Society
Fabienne DanhierVéronique Préat
© 2021 Meta ULC. All rights reserved